Drug Trial Radar · NCT06506461
Gene Editing For Sickle Cell Disease
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
25
Planned (sponsor's estimate)
Start
Mar 21, 2025
Primary completion
Dec 2029
Study completion Dec 2032
Sponsor
- Lead sponsor
- St. Jude Children's Research HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Heart, Lung, and Blood Institute (NHLBI)
- First posted
- Jul 17, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 24 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to test the safety of a new treatment called gene editing in Sickle Cell Disease (SCD) patients and to see if a single dose of this genetically modified cellular product will increase the amount of a certain hemoglobin called fetal hemoglobin (HbF) and help reduce the symptoms of SCD. Primary Objective * To assess the safety of autologous infusion of clustered regularly interspaced palindromic repeats (CRISPR)/ CRISPR associated protein (Cas9)-edited CD34+ hematopoietic stem and progenitor cells (HSPCs) in patients with severe SCD. Secondary Objective * To assess the efficacy autologous infusion of CRISPR/Cas9 genome-edited CD34+ HSPCs into patients with severe SCD.
Conditions
- Sickle Cell Disease
Interventions
PlerixaforDrug
Given Subcutaneous (under the skin)
BusulfanDrug
Given Intravenous (IV)
Gene-modified CD34+ cellsBiological
Given Intravenous (IV)
MotixafortideDrug
Given Subcutaneous (under the skin)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of neutrophil engraftment by day +42 after infusion of the CRISPR/Cas9-edited CD34+ HSPCs.Time frame: Within 42 days of the cellular product infusion
- Incidence of platelet engraftment by day +60 after infusion of the CRISPR/Cas9-edited CD34+ HSPCs.Time frame: Within 60 days of the cellular product infusion
- Sustenance of multi-lineage engraftment and polyclonal hematopoiesis as measured by counts of different clones of myeloid cells, T cells, B cells, and NK cells at 1 year after infusion of the CRISPR/Cas9-edited CD34+ HSPCs.Time frame: Within 1 year of the cellular product infusion
- Frequency of off-target editing after infusion of the CRISPR/Cas9-edited CD34+ HSPCs.Time frame: Within 3 years of the cellular product infusion
- Occurrence of secondary graft failure, clonal hematopoiesis, MDS, or AMLTime frame: Within 3 years of the cellular product infusion
Locations
1 site in 1 country. Site status is shown where the registry gives one.
St. Jude Children's Research Hospital
Memphis, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.